SHUKLA SANJAY (President and CEO) purchased 58.1% of their position (15K shares) of ATYR PHARMA INC on the open market
Open‑market purchase worth $43.2K — a major conviction buy. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 7/6/2022ACC: 0001209191-22-041230
Officer· President and CEO
Since Feb 2019
+15K
Net shares
Net buyer
$43.2K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
15K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+15K
Price / share
$2.88
Trade value
$43.16K
% of position
58.1%
7/1/2022
25.80K→40.80K
Total
Net shares
+15K
Net value
$43.16K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 7/1/2022 | P · Purchase | +15K | $2.88 | $43.16K | 58.1% | 25.80K | 40.80K |
| Total | +15K | $43.16K | ||||||
Derivative Transactions0
No derivative transactions reported